520 Results

People

  1. Postow
    Postow
  2. Motzer
    Motzer
  3. Wolchok
    Wolchok
  4. Hellmann
    Hellmann
  5. Shoushtari
    Shoushtari
  6. Voss
    Voss
  7. Callahan
    Callahan
  8. Abou-Alfa
    Abou-Alfa
  9. Jones
    Jones
  10. Rosenberg
    Rosenberg

Groups

  1. Department of Medicine (394)
  2. Solid Tumor Oncology Division (337)
  3. Hematologic Malignancies, Division of (108)
  4. Melanoma and Immunotherapeutics Service (108)
  5. Genitourinary Oncology Service (101)
  6. Melanoma Disease Management Team (96)
  7. GSK Faculty (83)
  8. Surgery (71)
  9. Gastrointestinal Oncology Service (65)
  10. Weinberg Fellows (61)
  1. "nivolumab"
Formats
  1. Journal Article (342)
  2. Review (93)
  3. Editorial (41)
  4. Meeting Abstract (18)
  5. Correspondence (7)
  6. Guidelines (7)
  7. Research Letter (6)
  8. Book Section (4)
  9. Conference Paper (1)
  10. Miscellaneous (1)
Groups
  1. Department of Medicine (394)
  2. Solid Tumor Oncology Division (337)
  3. Hematologic Malignancies, Division of (108)
  4. Melanoma and Immunotherapeutics Service (108)
  5. Genitourinary Oncology Service (101)
  6. Melanoma Disease Management Team (96)

More Groups

People
  1. Michael Postow (55)
  2. Robert Motzer (50)
  3. Jedd Wolchok (41)
  4. Margaret Callahan (28)
  5. Alexander Shoushtari (27)
  6. Matthew Hellmann (26)

More People

Years
  1. 2025 (35)
  2. 2024 (70)
  3. 2023 (75)
  4. 2022 (52)
  5. 2021 (45)
  6. 2020 (64)

More Years

Publications
  1. Journal for ImmunoTherapy of Cancer (23)
  2. Journal of Clinical Oncology (22)
  3. Journal of Thoracic Oncology (21)
  4. Lancet Oncology (21)
  5. New England Journal of Medicine (19)
  6. Annals of Oncology (17)

More Publications

Publishers
  1. Elsevier Inc. (77)
  2. Elsevier Science, Inc. (50)
  3. Oxford University Press (35)
  4. Wiley Blackwell (32)
  5. Biomed Central Ltd (27)
  6. Nature Publishing Group (27)

More Publishers

Results (520)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Therapeutic developments in pancreatic cancer
    Review

    Hu, Z. I.; O’Reilly, E. M.
    Nature Reviews Gastroenterology & Hepatology (2024)

    Fulltext@MSK | Save
  • Surgery for oligometastatic non–small cell lung cancer
    Editorial

    Antonoff, M. B.; Deboever, N.; Werner, R.; Altan, M.; Gomez, D.; Opitz, I.
    Journal of Thoracic and Cardiovascular Surgery (2024)

    Fulltext@MSK | Save
  • A brief report on the patterns of mediastinal nodal failure in resectable stage IB-IIIA NSCLC treated with neoadjuvant immunotherapy combinations, a secondary analysis of a prospective trial
    Journal Article

    Mao, S.; Rosner, S.; Forde, P. M.; Chaft, J. E.; Jones, D. R.; Spicer, J.; Hales, R. K.; Ha, J. S.; Hu, C.; Voong, K. R.
    Clinical Lung Cancer (2024)

    Fulltext@MSK | Save
  • Clinical outcomes of stereotactic body radiation therapy for malignant pleural mesothelioma
    Journal Article

    Shin, J. Y.; Offin, M.; Simone, C. B. 2nd; Zhang, Z.; Shepherd, A. F.; Wu, A. J.; Shaverdian, N.; Gelblum, D. Y.; Gomez, D. R.; Sauter, J. L.; more...
    Radiotherapy and Oncology (2024)

    Fulltext@MSK | Save
  • Adjuvant therapy for stage IIB + IIC melanoma
    Editorial

    Malekzadeh, P.; Brady, M. S.
    Journal of Surgical Oncology (2024)

    Fulltext@MSK | Save
  • Nivolumab and daratumumab combination regimens for the treatment of relapsed and refractory multiple myeloma: Results of a randomized phase I/II clinical trial
    Journal Article

    Abdallah, A. O.; Lesokhin, A.; Wrobel, T.; Jamroziak, K.; Dytfeld, D.; Touzeau, C.; Suvannasankha, A.; Leleu, X.; Silbermann, R.; Khan, A. M.; more...
    Frontiers in Hematology (2023)

    Fulltext@MSK | Save
  • Pathway alterations in stage II/III primary melanoma
    Journal Article

    Kostrzewa, C. E.; Luo, L.; Arora, A.; Seshan, V. E.; Ernstoff, M. S.; Edmiston, S. N.; Conway, K.; Gorlov, I.; Busam, K.; Orlow, I.; more...
    JCO Precision Oncology (2023)

    Fulltext@MSK | Save
  • Immune-related adverse events after immune checkpoint blockade-based therapy are associated with improved survival in advanced sarcomas
    Journal Article

    Rosenbaum, E.; Seier, K.; Bradic, M.; Kelly, C.; Movva, S.; Nacev, B. A.; Gounder, M. M.; Keohan, M. L.; Avutu, V.; Chi, P.; more...
    Cancer Research Communications (2023)

    Fulltext@MSK | Save
  • Real-world clinical outcomes of patients with metastatic renal cell carcinoma receiving pembrolizumab + axitinib vs. ipilimumab + nivolumab
    Journal Article

    Shah, N. J.; Sura, S. D.; Shinde, R.; Shi, J.; Singhal, P.; Perini, R. F.; Motzer, R. J.
    Urologic Oncology: Seminars and Original Investigations (2023)

    Fulltext@MSK | Save
  • Nivolumab plus ipilimumab in advanced salivary gland cancer: A phase 2 trial
    Journal Article

    Vos, J. L.; Burman, B.; Jain, S.; Fitzgerald, C. W. R.; Sherman, E. J.; Dunn, L. A.; Fetten, J. V.; Michel, L. S.; Kriplani, A.; Ng, K. K.; more...
    Nature Medicine (2023)

    Fulltext@MSK | Save